A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications†
Article first published online: 26 DEC 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 22, Issue 4, pages 386–393, April 2013
How to Cite
McAfee, A. T., Landon, J., Jones, M., Bangs, M. E., Acharya, N., Hornbuckle, K. and Wong, J. (2013), A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications. Pharmacoepidem. Drug Safe., 22: 386–393. doi: 10.1002/pds.3390
This research was conducted at OptumInsight (formerly i3 Drug Safety), Waltham, MA, USA and this was presented in abstract form at the 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (Copenhagen, Denmark) on August 18, 2008.
- Issue published online: 1 APR 2013
- Article first published online: 26 DEC 2012
- Manuscript Accepted: 19 NOV 2012
- Manuscript Revised: 14 NOV 2012
- Manuscript Received: 3 MAY 2012
- propensity scores;
- inception cohort;
Stimulant medications used for treating attention deficit hyperactivity disorder (ADHD) can be associated with an increased risk of seizures. Atomoxetine is a non-stimulant medication approved for treating ADHD. This retrospective cohort analysis evaluated risk of seizures among pediatric patients naïve to ADHD medication therapy, with exposure to atomoxetine relative to stimulant medications.
Among members of a large US health plan from 1/1/2003 to 12/31/2006, aged 6–17 years, we identified initiators of atomoxetine or stimulants with no evidence of prior study drug use. We created study cohorts using propensity score matching within 6-month calendar blocks. The outcome was a seizure event in the 6-month follow-up period verified through medical record review. Relative risks (RR) based on current use of each study drug adjusted for baseline covariates were calculated using Poisson regression. We estimated hazard ratios from Cox proportional hazards models for the comparison of atomoxetine to stimulants based on initial cohort assignment.
We matched 13 398 initiators of atomoxetine to 13 322 initiators of stimulants. We identified 97 seizure events. After adjustment, current atomoxetine therapy was associated with a non-statistically significant 28% lower risk of seizure compared to current stimulant therapy (RR 0.72; 95%CI 0.37, 1.38). The adjusted RR of seizure with atomoxetine compared to stimulants based on initial cohort assignment was 0.90 (95%CI 0.54, 1.49).
These results do not support an increase in the risk of seizure with atomoxetine therapy. The risk of seizure was not significantly different between pediatric patients taking atomoxetine compared with those taking stimulants. Copyright © 2012 John Wiley & Sons, Ltd.